Pharmaceutical Pipeline – Key Events in 2022*

POTENTIAL APPROVALS US/EU

✓ US EU **CARVYKTI (Ciltacabtagene autoleucel)**
Relapsed refractory Multiple Myeloma

EU **IMBRUVICA (ibrutinib)**
Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

US **IMBRUVICA (ibrutinib)**
Pediatric Chronic Graft Versus Host Disease

US **teclistamab (BCMA/CD3)**
Relapsed refractory Multiple Myeloma

✓ US **CABENUVA**
HIV Adolescents

US **STELARA (ustekinumab)**
Pediatric jPSA

PLANNED SUBMISSIONS US/EU

✓ EU **IMBRUVICA (ibrutinib)**
Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)

✓ EU **teclistamab (BCMA/CD3)**
Relapsed refractory Multiple Myeloma

✓ US **IMBRUVICA (ibrutinib)**
Pediatric Chronic Graft Versus Host Disease

EU **niraparib**
L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone

US **aprocitentan**
Difficult to treat hypertension

US **VAC18193**
RSV Adult Vaccine

US **VAC31518**
Janssen COVID-19 Vaccine

POTENTIAL CLINICAL DATA PRESENTATIONS

Phase III

CARVYKTI (Ciltacabtagene autoleucel)
Relapsed refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

DARZALEX (daratumumab)
Frontline multiple myeloma transplant ineligible (CEPHEUS)

IMBRUVICA (ibrutinib)
Relapsed/refractory Indolant Non-Hodgkins Lymphoma (SELENE)

✓ **niraparib**
L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)

aprocitentan
Difficult to treat hypertension (PRECISION RHTT)

Phase II

BALVERSA (erdafitinib)
Tumor Agnostic (RAGNAR)

milvexian (factor Xla)
Secondary stroke prevention (AXIOMATIC-SSP)

✓ **guselkumab/golimumab**
Ulcerative Colitis (VEGA)

✓ **guselkumab**
Ulcerative Colitis Monotherapy (QUASAR)

SPRAVATO (esketamine)
Pediatric Major Depressive Disorder with Suicidal Ideation or behavior (DIRECTION)

*This information is accurate as of April 19, 2022 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

✓ = Achieved